Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2015

View Archived Issues

Activation of engram cells by positive memories may suppress depression-related behaviors

Apceth and University of Cologne to develop cellular immunotherapies for cancer

Eligo Bioscience's development of antibiotics supported by new investment

Toulouse University Cancer Institute and Pierre Fabre sign framework agreement in oncology

Cleveland BioLabs reports data from phase I study of CBLB-612

Allegro Ophthalmics reports topline data from phase II study of Luminate

C3 Jian completes second phase II study of C16G2

Preliminary data presented on safety, PK and PD of PF-0538062 for hemophilia

FDA approves Iressa for metastatic NSCLC with certain EGFR mutations

Clozapine is a potent antiplatelet agent

Ferring to collaborate with Intralytix on bacteriophage therapy for IBD

Roche discloses V1A receptor antagonists

Cav2.2 blockers developed at Gruenenthal

Sunshine Lake Pharma reports 5-HT6 antagonists

Bayer Schering Pharma discloses EP4 antagonists

Bayer Schering Pharma presents alpha2C-adrenoceptor antagonists

RaQualia begins first-in-human study of 5-HT2B antagonist RQ-00310941

Anacor discloses positive results from phase III trials of crisaborole in atopic dermatitis

Phase III ENSPIRIT trial of custirsen sodium continues following final interim futility analysis

Blueprint Medicines receives FDA clearance to start phase I trials of BLU-554 and BLU-285

New phase I study investigates cabozantinib in combination therapy for genitourinary tumors

Results of in vivo neuroblastoma study of anisina plus vincristine

ACT-246475 shows a wider therapeutic window than ticagrelor

Researchers develop an improved p21 reporter mouse model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...